B7 homologous 3 (B7H3), an immune checkpoint molecule associated with poor prognosis, tumor progression, and immune suppression, is found to be upregulated in TECs and to dampen T-cell response, highlighting its potential role in regulating the vasculature and the immune evasion in TME [169,170]. The gene discussed is CD276; the disease is neoplasm.